Overview

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Diphosphonates
Raloxifene Hydrochloride
Zoledronic Acid